Skip to content


Eylea (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A and placenta growth factor. In addition, it is known to target vascular endothelial growth factor B.
Trade Name Eylea
Common Name Aflibercept
Indication colorectal neoplasms, diabetes complications, diabetic retinopathy, macular edema, wet macular degeneration
Drug Class Receptor molecules, native or modified: vascular endothelial growth factor (VEGF) receptors
Get full access now